TP53 and ovarian carcinoma: Our data suggest that in specific conditions Chk2 activation by Thr68 phosphorylation is regulated by p53 in response to cisplatin treatment in wt p53-contain cells, but not in p53-deficient cells, of human ovarian cancer.